CorrGene Biotech

Tests for Pyruvate Kinase Deficiency：
Enzyme Activity Test & Genetic Testing

How will Pyruvate kinase (PK) deficiency affect adults or children?

CorrGene:In March 2022, the CG001 pipeline of Pyruvate Kinase Deficiency obtained the European Medicines Agency (EMA) orphan drug status, discussed with the European Medicines Agency and successfully passed the pre-IND meeting, which will be synchronized in Europe and the United States in June 2023 clinical application
https://ec.europa.eu/health/documents/community-register/html/o2580.htm